Both the classical and alternative complement pathways result in the formation of the cytolysis inducing C5b-9 complex. This complex is composed of 190kD C5b which is bound to cells via 71kD C9. Sublytic assembly of C5b-9 on plasma membranes induces cell cycle activation and survival. The binding of C5b-9 to the 75kD S-protein (or vitronectin) in the fluid phase prevents C5b-9 from assembling on the plasma membrane, deactivating it and forming the SC5b-9 complex. SC5b-9 is stable in vitro and is therefore a reliable indicator of terminal complement pathway activation.
Suitable for use in ELISA, Flow Cytometry, Western Blot and Immunohistochemistry. Other applications not tested.
Optimal dilutions to be determined by the researcher.
Immunohistochemistry Positive Control:
Kidney from post streptoccal glomerulonephritis patients.
Recommended Secondary Antibodies:
I1904-06C: IgG, H&L (HRP) (X-Adsorbed) Pab Gt xMo
I1904-06H IgG, H&L (HRP) (X-Adsorbed) Pab Gt xMo
I1904-14C: IgG, (HRP) Pab Gt xMo
I1904-19C: IgG, (HRP) Pab Gt xMo
Storage and Stability:
May be stored at 4 degrees C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20 degrees C. Aliquots are stable for 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.